Intelligent Investor

Medibank appoints new chief

Australia's largest private health insurer has picked a banking executive for the top job.
By · 29 Mar 2016
By ·
29 Mar 2016 · 2 min read
Upsell Banner

Recommendation

Medibank Private Limited - MPL
Buy
below 1.60
Hold
up to 2.80
Sell
above 2.80
Buy Hold Sell Meter
HOLD at $2.85
Current price
$3.59 at 16:40 (19 April 2024)

Price at review
$2.85 at (29 March 2016)

Max Portfolio Weighting
5%

Business Risk
Medium

Share Price Risk
Medium
All Prices are in AUD ($)

Medibank Private has appointed Craig Drummond as its next chief executive following the departure of George Savvides in April. Drummond was previously Group Executive of Finance and Strategy at National Australia Bank, where his responsibility was the 'strategic realignment and repositioning of the bank, its balance sheet and performance management systems,' the company said.

Prior to his role at NAB, Drummond was head of the Australian operations of Bank of America Merrill Lynch. Following his appointment in 2009, he helped return the business to profitability following the global financial crisis. Other posts include various senior roles at Goldman Sachs where he oversaw the merger of JBWere and Goldman Sachs Australia in 2003.

Medibank's chairman Elizabeth Alexander said Drummond 'has an outstanding reputation for his leadership capabilities, strategic thinking and business acumen. He brings with him deep experience in regulated service industries requiring a strong customer focus'.

We've been critical of current management in the past (see Medibank's slippery slope). Although recent results have been decent and Medibank's margins are now in line with the rest of the industry, we're happy to see a change of the guard.

We look forward to hearing more from Drummond himself at the full year result. In particular, we're interested in whether he'll continue Medibank's current strategy of investing in primary care and GPs to reduce chronic disease, rather than simply tackling claims when they arrive down the track.

Medibank's share price is hovering close to our recommended Sell price and the stock has a price-earnings ratio of 21. It isn't cheap, though we'll give the stock more leeway before officially downgrading. HOLD

IMPORTANT: Intelligent Investor is published by InvestSMART Financial Services Pty Limited AFSL 226435 (Licensee). Information is general financial product advice. You should consider your own personal objectives, financial situation and needs before making any investment decision and review the Product Disclosure Statement. InvestSMART Funds Management Limited (RE) is the responsible entity of various managed investment schemes and is a related party of the Licensee. The RE may own, buy or sell the shares suggested in this article simultaneous with, or following the release of this article. Any such transaction could affect the price of the share. All indications of performance returns are historical and cannot be relied upon as an indicator for future performance.
Share this article and show your support

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here